Skip to main content

Table 1 Patient characteristics

From: A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

 

Patients

n

%

Age, years [median (range)]

78 (70–84)

 

Sex

 Female

6

37.5

 Male

10

62.5

ECOG PS

 0

5

31.3

 1

5

31.3

 2

6

37.4

Histology

 Adenocarcinoma

11

68.8

 Squamous cell carcinoma

2

12.5

 Adenosquamous cell carcinoma

1

6.2

 NOS

2

12.5

Clinical stage (TNM ver.7)

 IIIB

4

25.0

 IV

11

68.8

 Post operative recurrence

1

6.2

No. of prior chemotherapy regimen

 1

15

93.8

 2

1

6.2

  1. ECOG PS Eastern Cooperative Oncology Group performance status, TNM tumor-node-metastasis, NOS not otherwise specified.